Order Article Reprints

Demirkiran C, Bellone S, Ettorre VM, Mansolf M, Hartwich TMP, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin NG, et al. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal of Molecular Sciences. 2025; 26(18):8924. https://doi.org/10.3390/ijms26188924

Demirkiran, Cem, Stefania Bellone, Victoria M. Ettorre, Miranda Mansolf, Tobias Max Philipp Hartwich, Blair McNamara, Michelle Greenman, Yang Yang-Hartwich, Elena Ratner, Niccoló G. Santin, and et al. 2025. "Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor" International Journal of Molecular Sciences 26, no. 18: 8924. https://doi.org/10.3390/ijms26188924

Demirkiran, C., Bellone, S., Ettorre, V. M., Mansolf, M., Hartwich, T. M. P., McNamara, B., Greenman, M., Yang-Hartwich, Y., Ratner, E., Santin, N. G., Sethi, N., Palmieri, L., Coma, S., Pachter, J. A., Ottum, S., & Santin, A. D. (2025). Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal of Molecular Sciences, 26(18), 8924. https://doi.org/10.3390/ijms26188924